Natural Products
- ChemFaces is a professional high-purity natural products manufacturer.
- Product Intended Use
- 1. Reference standards
- 2. Pharmacological research
- 3. Inhibitors
| Size /Price /Stock | 10 mM * 1 mL in DMSO / $12.7 / In-stock | Other Packaging | *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap |
| Description: | 1. Lupeol has a potential to act as an anti-inflammatory, anti-microbial, anti-protozoal, anti-proliferative, anti-invasive, anti-angiogenic, antimalarial and cholesterol lowering agent. 2. Lupeol prevents acetaminophen-induced in vivo hepatotoxicity by altering the Bax/Bcl-2 and oxidative stress-mediated mitochondrial signaling cascade. 3. Lupeol and its ester derivative have beneficial effects on hypercholesterolemia-induced oxidative and inflammatory stresses. 4. Lupeol significantly enhances the radiosensitivity of SMMC-7721 cells in vitro and in vivo. 5. Lupeol shows antidiabetic and antioxidant potential in experimental hyperglycaemia. 6. Lupeol has potential anticancer effect against hepatocellular and pancreatic cancer, by inhibiting cell proliferation, inducing apoptosis and blocking Akt/PI3K and Wnt signaling pathway. 7. Lupeol has antiangiogenic effects, it (at 50 and 30 microg/mL) shows a marked inhibitory activity on human umbilical venous endothelial cells (HUVEC) tube formation while it does not affect the growth of tumor cell lines such as SK-MEL-2, A549, and B16-F10 melanoma. | |||
| Targets: | Caspase | PARP | GSK-3 | Akt | PI3K | Wnt/β-catenin | c-Myc | IL Receptor | Bcl-2/Bax | NF-kB | ROS | TNF-α | STAT | |||
| In vitro: |
|
| Source: | The flower of Chrysanthemum morifolium |
| Solvent: | Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc. |
| Storage: | Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C). Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com |
| After receiving: | The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling. |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3436 mL | 11.7178 mL | 23.4357 mL | 46.8713 mL | 58.5892 mL |
| 5 mM | 0.4687 mL | 2.3436 mL | 4.6871 mL | 9.3743 mL | 11.7178 mL |
| 10 mM | 0.2344 mL | 1.1718 mL | 2.3436 mL | 4.6871 mL | 5.8589 mL |
| 50 mM | 0.0469 mL | 0.2344 mL | 0.4687 mL | 0.9374 mL | 1.1718 mL |
| 100 mM | 0.0234 mL | 0.1172 mL | 0.2344 mL | 0.4687 mL | 0.5859 mL |
| Citation [1] Int J Radiat Biol. 2015 Feb;91(2):202-8. | Lupeol enhances radiosensitivity of human hepatocellular carcinoma cell line SMMC-7721 in vitro and in vivo.[Pubmed: 25241960] |
| PURPOSE: To investigate the effect of Lupeol, a pentacyclictriterpene, on the radiosensitivity of a human hepatocellular carcinoma (HCC) in vitro and in vivo xenografts. METHODS: SMMC-7721 cells were exposed to γ-radiation with or without Lupeol and assayed for proliferation, clonogenic survival, apoptosis and cell cycle distribution. The cells were also analyzed by Western blotting for the expression levels of the proteins involved in apoptosis. Finally radiosensitization by Lupeol was assessed in HCC xenograft model. RESULTS: Lupeol further suppressed the proliferation and colonogenic survival of the SMMC-7721 cells exposed to γ-radiation. It could also induce the accumulation of cells in G2/M phase together with γ-radiation. The data also indicated that Lupeol sensitized SMMC-7721 cells exposed to γ-radiation to apoptosis and activated the apoptotic proteins including caspase-9 and PARP. Administration of Lupeol with radiation in HCC xenograft model produced a significant tumor growth delay compared with radiation or Lupeol alone and was well tolerated. CONCLUSION: Lupeol significantly enhanced the radiosensitivity of SMMC-7721 cells in vitro and in vivo. The mechanisms involved could be cell cycle arrest and induction of apoptosis. Our studies suggest that Lupeol has the potential to be developed as an adjuvant for radiotherapy in HCC. | |
| Citation [2] Eur J Pharmacol. 2015 May 21;762:55-62. | A novel mechanism of hepatocellular carcinoma cell apoptosis induced by lupeol via Brain-Derived Neurotrophic Factor Inhibition and Glycogen Synthase Kinase 3 beta reactivation.[Pubmed: 26004524] |
| Lupeol is a naturally available triterpenoid with selective anticancerous potential on various human cancer cells. The present study shows that Lupeol can inhibit cell proliferation of hepatocellular carcinoma (HCC) HCCLM3 cells in a time- and dose-dependent manner, through caspase-3 dependent activation and Poly ADP-Ribose Polymerase (PARP) cleavage. Lupeol-induced cell death is associated with a marked decrease in the protein expression of Brain-Derived Neurotrophic Factor (BDNF) and ser-9-phosphoryltion of Glycogen Synthase Kinase 3 Beta (GSK-3β), with concomitant suppression of Akt1, phosphatidyl inositol 3-kinase (PI3K), β-catenin, c-Myc and Cyclin D1 mRNA expression. Suppressing overexpression of BDNF by Lupeol results in decreased protein expression of p-Akt and PI3K (p110α), as well as reactivation of GSK-3β function in HepG2 cells. Lupeol treatment also inhibits LiCl-induced activation of Wnt signaling pathway and exerts the in vitro anti-invasive activity in Huh-7 cells. LiCl-triggered high expression of β-catenin, c-Myc and Cyclin D1 protein is reduced followed by Lupeol exposure. The findings suggest a mechanistic link between caspase dependent pathway, BDNF secretion and Akt/PI3K/GSK-3β in HCC cells. These results indicate that Lupeol can suppress HCC cell proliferation by inhibiting BDNF secretion and phosphorylation of GSK-3β(Ser-9), cooperated with blockade of Akt/PI3K and Wnt signaling pathway. | |
| Citation [3] Life Sci. 2011 Feb 14;88(7-8):285-93. | Beneficial health effects of lupeol triterpene: a review of preclinical studies.[Pubmed: 21118697 ] |
| Since ancient times, natural products have been used as remedies to treat human diseases. Lupeol, a phytosterol and triterpene, is widely found in edible fruits, and vegetables. Extensive research over the last three decades has revealed several important pharmacological activities of Lupeol. Various in vitro and preclinical animal studies suggest that Lupeol has a potential to act as an anti-inflammatory, anti-microbial, anti-protozoal, anti-proliferative, anti-invasive, anti-angiogenic and cholesterol lowering agent. Employing various in vitro and in vivo models, Lupeol has also been tested for its therapeutic efficiency against conditions including wound healing, diabetes, cardiovascular disease, kidney disease, and arthritis. Lupeol has been found to be pharmacologically effective in treating various diseases under preclinical settings (in animal models) irrespective of varying routes of administration viz; topical, oral, intra-peritoneal and intravenous. It is noteworthy that Lupeol has been reported to selectively target diseased and unhealthy human cells, while sparing normal and healthy cells. Published studies provide evidence that Lupeol modulates the expression or activity of several molecules such as cytokines IL-2, IL4, IL5, ILβ, proteases, α-glucosidase, cFLIP, Bcl-2 and NFκB. This minireview discusses in detail the preclinical studies conducted with Lupeol and provides an insight into its mechanisms of action. | |
| Citation [4] Life Sci. 2012 Apr 20;90(15-16):561-70. | Lupeol prevents acetaminophen-induced in vivo hepatotoxicity by altering the Bax/Bcl-2 and oxidative stress-mediated mitochondrial signaling cascade.[Pubmed: 22326499 ] |
| AIMS: Lupeol, a triterpene, possesses numerous pharmacological activities, including anti-malarial, anti-arthritic and anti-carcinogenic properties. The present study was conducted to explore the hepatoprotective potential of Lupeol against acetaminophen (AAP)-induced hepatotoxicity in Wistar rats.KEY FINDINGS: Lupeol significantly prevented hepatic damage as evident from the histopathological studies and significant decline in serum trans-aminases. The alterations in cellular redox status (p<0.01) and antioxidant enzyme activities together with the enhanced lipid peroxidation and protein carbonyl levels were also observed in the AAP-treated rats. In addition, significant ROS generation and mitochondrial depolarization were observed in this group. Co-administration of Lupeol significantly decreased the level of serum transaminases, MDA and protein carbonyl content. It also prevented ROS generation and mitochondrial depolarization. Furthermore, Lupeol enhanced the mitochondrial antioxidant and redox status and inhibited DNA damage and cell death by preventing the downregulation of Bcl-2, upregulation of Bax, release of cytochrome c and the activation of caspase 9/3. SIGNIFICANCE: The conclusion of this study is that Lupeol when co-administered with AAP effectively reduces oxidative stress and prevents AAP-induced hepatotoxicity by inhibiting critical control points of apoptosis. | |
| Citation [5] Orbital the Electronic Journal of Chemistry, 2012, 4(1):21-2. | Synthesis of triazol derivatives of lupeol with potential antimalarial activity.[Reference: WebLink] |
| The goal of this project is synthesize and characterization of derivatives of Lupeol and evaluated antimalarial activity. Historically, plants are important source of antimalarial medicines, highlighting quinine (1) (Figure 1), an important alkaloid from the Cinchona calisaya bark. This compound was an important model for cloroquine synthesis, a drug that was widely used in malaria treatment. In addition, one of the principal medicines used today is artemisinine, isolated from the Chinese plant Artemisia annua L (2) (Figure 1), and their semi synthetic derivatives (artesunate, artemeter, arteter). However, the malaria parasite has already shown resistance to most of these current drugs and the search for new candidates is essential. Lupeol (3) (Figura 1) is a compound that occurs in many plant species and discloses antimalarial, antiinflamatoryl and antitumoral activities. Considering its potential as a lead antimalarial molecule, we focused our work in the synthesis of new Lupeol derivatives with increased antimalarial activity(scheme 1). | |
| Citation [6] Phytother Res. 2003 Apr;17(4):341-4. | Antiangiogenic activity of lupeol from Bombax ceiba.[Pubmed: 12722136 ] |
| In the search for antiangiogenic agents from medicinal plants used in Vietnam, a methanol extract of the stem barks of Bombax ceiba was found to exhibit a significant antiangiogenic activity on in vitro tube formation of human umbilical venous endothelial cells (HUVEC). Bioactivity-guided fractionation and isolation carried out on this extract afforded Lupeol as an active principle. At 50 and 30 microg/mL Lupeol showed a marked inhibitory activity on HUVEC tube formation while it did not affect the growth of tumor cell lines such as SK-MEL-2, A549, and B16-F10 melanoma. | |
| Citation [7] Nutr. Res., 2007, 27(12):778-87. | Remedial effect of lupeol and its ester derivative on hypercholesterolemia-induced oxidative and inflammatory stresses.[Reference: WebLink] |
| The pentacyclic triterpene, Lupeol, and the ester derivative of Lupeol, Lupeol linoleate, were supplemented (50 mg/kg body weight per day, PO) during the last 15 days. Oxidative stress in HCD-fed animals was characterized by a significant increase in reactive oxygen species with concomitant decrease in the thiol levels in heart. Cardiac nuclear factor-κB nuclear translocation was confirmed by immunohistochemisty in HCD-fed rats. The tumor necrosis factor-α levels showed an increase in hypercholesterolemic condition, whereas a departure toward control values and decreased nuclear translocation of nuclear factor-κB and oxidative stress were notable in supplementation with triterpenes. The nitric oxide levels and mRNA expression for inducible nitric oxide synthase was also significantly increased in HCD-fed animals. Treatment with Lupeol and Lupeol linoleate reversed the nitrosative stress to near normalcy. These observations highlight the beneficial effects of the triterpene, Lupeol, and linoleate ester in ameliorating the oxidative and inflammatory abnormalities in the hypercholesterolemic conditions. | |
| Citation [8] Nat Prod Res. 2012;26(12):1125-9. | Evaluation of antidiabetic and antioxidant potential of lupeol in experimental hyperglycaemia.[Pubmed: 22043924] |
| Oxidative stress, produced under diabetic conditions, is a possible cause of various forms of tissue damage. The concentrations of antioxidant enzymes in cases of diabetes are significantly decreased, with a concomitant increase in lipid peroxidation. In this study, Lupeol, a phytoconstituent from Solanum xanthocarpum, is shown to suppress the progression of diabetes after 21 days. Lupeol treatment caused decreases in glycated haemoglobin, serum glucose and nitric oxide, with a concomitant increase in serum insulin level. Furthermore, treatment with Lupeol also increased antioxidant levels, with a decrease in the level of thiobarbituric acid-reactive oxygen species. |
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)